R&D Returns Shrink to Lowest Level in Decade, Analysis Finds

Drug Industry Daily
A A
Drug companies’ returns on R&D investments have sunk to their lowest level since 2010 and analysts at Deloitte attribute the decline mostly to the soaring costs of clinical trials.

To View This Article:

Login

Subscribe To Drug Industry Daily